Olaparib maintenance treatment can significantly decrease the IL‐6 and TNF‐α level, and increase IFN‐γ level and the CD4+/CD8+ ratio in patients with recurrent ovarian cancer. The gene discussed is TNF; the disease is ovarian carcinoma.